Prosecution Insights
Prosecution Insights
27 pending office actions • 21 art units • 26 examiners • 0 of 27 (0%) have an AI response strategy ready • 39 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 27 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 27 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (4%) |
| §103 only | 13 (48%) |
| §112 only | 3 (11%) |
| No statute on record | 10 (37%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KAUFMAN, CLAIRE M | 2 | 62.8% | +51.3% |
| LOVE, TREVOR M | 1 | 43.1% | +25.4% |
| BERRY, LAYLA D | 1 | 65.9% | +8.6% |
| TRAN, SUSAN T | 1 | 62.8% | +36.0% |
| LIU, SUE XU | 1 | 20.6% | +15.4% |
| MIKNIS, ZACHARY J | 1 | 68.5% | +32.6% |
| MCDOWELL, BRIAN E | 1 | 74.3% | +30.6% |
| JAUHARI, SACHI | 1 | 0.0% | +0.0% |
| MOTEVALLI, OROD | 1 | — | — |
| MCCOLLUM, ANDREA K | 1 | 60.7% | +32.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17999122 | VIRAL VECTORS AND NUCLEIC ACIDS FOR REGULATED GENE THERAPY | SHIN, DANA H | 23d overdue |
| 18544532 | SOLID DISPERSION OF A HER2 INHIBITOR | LIU, SUE XU | 26d |
| 18450487 | COMBINATION THERAPY COMPRISING LONG ACTING GLP-1/GLUCAGON AND NPY2 RECEPTOR AGONISTS | JAUHARI, SACHI | 55d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18353133 | ANTI-IL-36R ANTIBODY FORMULATIONS | MCCOLLUM, ANDREA K | 44d overdue |
| 18746567 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | LOVE, TREVOR M | 28d overdue |
| 18508346 | BINDING MOLECULES FOR THE TREATMENT OF CANCER | KAUFMAN, CLAIRE M | 5d |
| 18515654 | VIRAL VECTOR FOR THE TARGETED TRANSFER OF GENES IN THE BRAIN AND SPINAL CORD | MIKNIS, ZACHARY J | 9d |
| 17414970 | BIFUNCTIONAL ANTI-PD-1/IL-7 MOLECULE | KAUFMAN, CLAIRE M | 16d |
| 18468885 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | MCDOWELL, BRIAN E | 22d |
| 18544532 | SOLID DISPERSION OF A HER2 INHIBITOR | LIU, SUE XU | 26d |
| 18413822 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF | TRAN, SUSAN T | 28d |
| Art Unit | Apps |
|---|---|
| 1674 | 3 |
| 1624 | 3 |
| 1642 | 2 |
| 1631 | 2 |
| 1611 | 1 |
| 1693 | 1 |
| 1615 | 1 |
| 1616 | 1 |
| 1658 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18746567 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | LOVE, TREVOR M | 1611 | §103 | Final Rejection | 28d overdue | Pending | Jun 18, 2024 |
| 18597314 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT | BERRY, LAYLA D | 1693 | Other | Non-Final OA | 66d overdue | Pending | Mar 06, 2024 |
| 18413822 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF | TRAN, SUSAN T | 1615 | §103 | Final Rejection | 28d | Pending | Jan 16, 2024 |
| 18544532 | SOLID DISPERSION OF A HER2 INHIBITOR | LIU, SUE XU | 1616 | Other | Non-Final OA | 26d | Pending | Dec 19, 2023 |
| 18515654 | VIRAL VECTOR FOR THE TARGETED TRANSFER OF GENES IN THE BRAIN AND SPINAL CORD | MIKNIS, ZACHARY J | 1658 | §112 | Final Rejection | 9d | Pending | Nov 21, 2023 |
| 18508346 | BINDING MOLECULES FOR THE TREATMENT OF CANCER | KAUFMAN, CLAIRE M | 1674 | Other | Non-Final OA | 5d | Pending | Nov 14, 2023 |
| 18468885 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | MCDOWELL, BRIAN E | 1624 | §112 | Non-Final OA | 22d | Pending | Sep 18, 2023 |
| 18450487 | COMBINATION THERAPY COMPRISING LONG ACTING GLP-1/GLUCAGON AND NPY2 RECEPTOR AGONISTS | JAUHARI, SACHI | 1654 | §103 | Non-Final OA | 55d | Pending | Aug 16, 2023 |
| 18362034 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | MOTEVALLI, OROD | 1628 | Other | Non-Final OA | 26d overdue | Pending | Jul 31, 2023 |
| 18353133 | ANTI-IL-36R ANTIBODY FORMULATIONS | MCCOLLUM, ANDREA K | 1674 | Other | Non-Final OA | 44d overdue | Pending | Jul 17, 2023 |
| 18221936 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | MOORE, SUSANNA | 1624 | §103 | Final Rejection | 28d | Pending | Jul 14, 2023 |
| 18337693 | MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT | GODDARD, LAURA B | 1642 | Other | Final Rejection | 5d | Pending | Jun 20, 2023 |
| 18334454 | PERFUSION MEDIUM | BARRON, SEAN C | 1653 | §103 | Non-Final OA | 70d | Pending | Jun 14, 2023 |
| 18039433 | ADMINISTRATION DEVICE FOR IN PARTICULAR INTRAVITREAL ADMINISTRATION OF A FLUID | BRANDT, DAVID NELSON | 3783 | §103 | Non-Final OA | 30d | Pending | May 30, 2023 |
| 18298882 | COMBINATION TREATMENT | SHIBUYA, MARK LANCE | 1631 | §103 | Non-Final OA | 15d | Pending | Apr 11, 2023 |
| 18185493 | ANG2-BINDING MOLECULES | MOSELEY II, NELSON B | 1642 | Other | Non-Final OA | 5d | Pending | Mar 17, 2023 |
| 18019771 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | HABTE, KAHSAY | 1624 | §112 | Non-Final OA | 4d overdue | Pending | Feb 03, 2023 |
| 18057421 | CELL CULTURE MEDIUM | JOHNSON, KARA D | 1632 | §103 | Final Rejection | 18d overdue | Pending | Nov 21, 2022 |
| 17999122 | VIRAL VECTORS AND NUCLEIC ACIDS FOR REGULATED GENE THERAPY | SHIN, DANA H | 1635 | §101 | Non-Final OA | 23d overdue | Pending | Nov 17, 2022 |
| 17914773 | INHIBITORS OF TRPC6 FOR TREATING RESPIRATORY CONDITIONS | RZECZYCKI, PHILLIP MATTHEW | 1625 | Other | Non-Final OA | 31d overdue | Pending | Sep 27, 2022 |
| 17914373 | USE OF BIOMARKERS IN THE TREATMENT OF FIBROTIC CONDITIONS | BOESEN, CHRISTIAN C | 1684 | §103 | Non-Final OA | 5d | Pending | Sep 26, 2022 |
| 17904487 | MAMMALIAN CELL CULTURE PROCESSES | MIANO, JOSEPH PAUL | 1631 | §103 | Non-Final OA | 73d overdue | Pending | Aug 18, 2022 |
| 17686880 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF | TIEN, LUCY MINYU | 1612 | §103 | Non-Final OA | 56d overdue | Pending | Mar 04, 2022 |
| 17530559 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF | KASSA, TIGABU | 1619 | §103 | Non-Final OA | 72d overdue | Pending | Nov 19, 2021 |
| 17525433 | CELL ENGINEERING USING RNAs | HOLLAND, PAUL J | 1656 | §103 | Non-Final OA | 34d | Pending | Nov 12, 2021 |
| 17608328 | VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF PF-ILD AND IPF | ZAHORIK, AMANDA MARY | 1636 | Other | Non-Final OA | 119d overdue | Pending | Nov 02, 2021 |
| 17414970 | BIFUNCTIONAL ANTI-PD-1/IL-7 MOLECULE | KAUFMAN, CLAIRE M | 1674 | Other | Non-Final OA | 16d | Pending | Jun 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial